Active Ingredient History
Citalopram hydrobromide (citalopram HB) belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). It is sold under the brand name Celexa and is indicated for the treatment of depression. The mechanism of action of citalopram HBr is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Citalopram is a racemic mixture, and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer. Citalopram can be used off-label for the treatment of anxiety, autism, dementia, alcoholism, diabetic neuropathy, eating disorders such as anorexia and bulimia, premature ejaculation and many others. Citalopram causes dose-dependent QT interval prolongation which is why it isno longer prescribed at doses greater than 40 mg per day. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Pain (Phase 2/Phase 3)
Acute Coronary Syndrome (Phase 4)
Alcoholism (Phase 2)
Alzheimer Disease (Phase 3)
Anhedonia (Phase 1/Phase 2)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Autism Spectrum Disorder (Phase 1)
Autistic Disorder (Phase 2)
Bereavement (Phase 2)
Bipolar Disorder (Phase 4)
Bone Diseases (Phase 3)
Borderline Personality Disorder (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Breast Neoplasms (Phase 3)
Burning Mouth Syndrome (Phase 3)
Chorea (Phase 2)
Citalopram (Phase 2)
Cocaine-Related Disorders (Phase 2)
Comorbidity (Phase 4)
Dementia (Phase 4)
Dementia, Vascular (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Drug Interactions (Phase 1)
Dysthymic Disorder (Phase 2)
Executive Function (Phase 2)
Fecal Incontinence (Phase 1)
Friedreich Ataxia (Phase 4)
Frontotemporal Dementia (Phase 4)
Gastroesophageal Reflux (Phase 4)
Grief (Phase 2)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 4)
Hepatitis C (Phase 4)
HIV (Phase 1)
HIV Infections (Phase 3)
Hot Flashes (Phase 3)
Huntington Disease (Phase 2)
Irritable Bowel Syndrome (Phase 2)
Ischemic Stroke (Phase 2)
Mandibular Diseases (Phase 2/Phase 3)
Menopause (Phase 2)
Mental Disorders (Phase 4)
Mood Disorders (Phase 2)
Motor Activity (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Myocardial Infarction (Phase 4)
Myofascial Pain Syndromes (Phase 2/Phase 3)
Neoplasms (Phase 3)
Neurodevelopmental Disorders (Phase 2)
Obsessive-Compulsive Disorder (Phase 4)
Opioid-Related Disorders (Phase 2)
Pain (Phase 4)
Parkinson Disease (Phase 2)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Schizophrenia (Phase 4)
Stroke (Phase 4)
Suicide (Phase 4)
Suicide, Attempted (Phase 2/Phase 3)
Urinary Incontinence, Stress (Phase 1)
Whiplash Injuries (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
